The approval is supported by data from the phase 3 VOLGA trial.
|Videos|October 13, 2020
Dr. Ben Chew discusses kidney stones and metabolic syndrome
Author(s)Urology Times staff
"Treat the patient as a whole, not just as a stone former," Chew advises.
Advertisement
In this interview, Ben H. Chew, MD, MSc, associate professor of urologic sciences at the University of British Columbia, Vancouver, discusses findings from the recent Journal of Endourology paper, “Metabolic Syndrome Negatively Impacts Stone-Specific Quality of Life,” for which he served as a study author.
Advertisement
Related to this article
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
4
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
5